~~<i id='25DD61ADA3'><strike id='25DD61ADA3'><tt id='25DD61ADA3'><pre id='25DD61ADA3'></pre></tt></strike></i>~~

Home» explore» leisure time

leisure time

author：leisure time 2025-09-28 10:52:15 Page View：396

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare has a new plan to address drug shortages
Next article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

comprehensive

Moonlake's readout produced a cash windfall. Risks remain

MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

Gene therapy’s promise and the high cost of hope

AdobeAtthebustlingChicagoO’Hareairport,myluggageandIcollidedwithanelderlycouple.MyheartsankwhenIreal

Walensky prepares to leave CDC — and Congress — behind

OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

Key Senate panel to consider PBM, drug pricing reform package

Sens.RonWydenandMikeCrapointroducedamentalhealth,PBMreformandsubstanceusepolicypackage.DrewAngerer/G